Cargando…
Efficacy of nebivolol‐valsartan single‐pill combination in obese and nonobese patients with hypertension
Antihypertensive efficacy of single‐pill combinations (SPCs) consisting of a β(1)‐selective adrenergic blocker with vasodilatory properties via β(3)‐agonism (nebivolol) and an angiotensin II receptor blocker (valsartan) was demonstrated in an 8‐week phase 3 trial (NCT01508026). In this post hoc anal...
Autores principales: | Mende, Christian W., Giles, Thomas D., Bharucha, David B., Ferguson, William G., Mallick, Madhuja, Patel, Mehul D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484387/ https://www.ncbi.nlm.nih.gov/pubmed/28075064 http://dx.doi.org/10.1111/jch.12965 |
Ejemplares similares
-
Additivity of nebivolol/valsartan single‐pill combinations versus other single‐pill combinations for hypertension
por: Ishak, Jack, et al.
Publicado: (2017) -
Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data
por: Giles, Thomas D., et al.
Publicado: (2017) -
Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study
por: Mody, Reema, et al.
Publicado: (2019) -
Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan
por: Varagic, Jasmina, et al.
Publicado: (2014) -
Simultaneous Estimation of Nebivolol Hydrochloride and Valsartan using RP HPLC
por: Kokil, S. U., et al.
Publicado: (2009)